Snibe Diagnostic

CE REF 130201015M: 100 tests
130601015M: 50 tests

MAGLUMI® CA 72-4 (CLIA)

INTENDED USE

The kit is an *in vitro* chemiluminescence immunoassay for the quantitative determination of Cancer Antigen 72-4 (CA 72-4) in human serum with the MAGLUMI series Fully-auto chemiluminescence immunoassay analyzer (including Maglumi 600, Maglumi 800, Maglumi 1000, Maglumi 1000 Plus, Maglumi 2000, Maglumi 2000 Plus, Maglumi 4000, Maglumi 4000 Plus, MAGLUMI X8, MAGLUMI X3 and MAGLUMI X6) and Biolumi series Integrated System (including Biolumi CX8).

SUMMARY AND EXPLANATION OF THE TEST

Tumor-associated glycoprotein-72 (TAG-72), which can be measured like CA 724, is a glycoprotein found on the surface of many cancer cells. It is expressed in a wide range of human carcinomas but has little or no staining in lymphomas, mesotheliomas, neural tumors, sarcomas, or benign tumours. CA 72-4 is generally not found in normal adult tissue, but with the exception of secretory endometrium[1].

CA 72-4 has been used for diagnosing gastric cancer and epithelial ovarian cancer. In combination of other marker such as CA 19-9 and CEA, CA 72-4 is also used to determine if colorectal cancer is still present following surgical removal or if the cancer has recurred following complete surgical removal, and to monitor how well the patient is responding to therapy[2-3]. The addition of CA 72-4 to CEA and CA 19-9, improving sensitivity, compared to one of these markers alone, could be useful in the monitoring of gastric cancer, either to detect recurrence after surgery, or to assess the efficacy of chemotherapy given for an advanced disease[2].

When the patients with gastric cancer were divided into 2 groups, initial (stage I/II) and advanced disease(stage III/IV), CA 72-4 was the best marker (60.6%) for advanced disease. CA 72-4 could also be used to monitor recurrence or metastasis in those cases that had elevated serum levels prior to surgery[4-8].

PRINCIPLE OF THE TEST

The CA 72-4 assay is a sandwich chemiluminescence immunoassay.

The sample (or calibrator/control, if applicable), ABEI labeled with anti-CA 72-4 monoclonal antibody, buffer, magnetic microbeads coated with another anti-CA 72-4 monoclonal antibody are mixed thoroughly and incubated. After precipitation in a magnetic field, decant the supernatant, and then perform a wash cycle. Subsequently, the Starter 1+2 are added to initiate a flash chemiluminescent reaction. The light signal is measured by a photomultiplier as relative light units (RLUs), which is proportional to the concentration of CA 72-4 present in the sample (or calibrator/control, if applicable).

KIT COMPONENTS

Material Provided

Components	Contents	100 tests (REF: 130201015M)	50 tests (REF: 130601015M)
Magnetic Microbeads	Magnetic microbeads coated with anti- CA 72-4 monoclonal antibody, containing BSA, NaN_3 (<0.1%).	2.5 mL	2.0 mL
Calibrator Low	Containing BSA and CA 72-4 antigen, NaN_3 (<0.1%).	2.5 mL	2.0 mL
Calibrator High	Containing BSA and CA 72-4 antigen, NaN_3 (<0.1%).	2.5 mL	2.0 mL
Buffer	Containing BSA, NaN_3 (<0.1%).	10.5 mL	6.5 mL
ABEI Label	Anti-CA 72-4 monoclonal antibody labeled with ABEI, containing BSA, NaN_3 (<0.1%).	10.5 mL	6.5 mL
Internal Quality Control	Containing BSA and CA 72-4 antigen, NaN_3 (<0.1%).	2.0 mL	2.0 mL
All reagents are provided ready-to-use.			

Accessories Required But Not Provided

MAGLUMI and Biolumi Series:

Reaction Module	REF: 630003
Starter 1+2	REF: 130299004M, 130299027M
Wash Concentrate	REF: 130299005M
Light Check	REF: 130299006M
Reaction Cup	REF: 130105000101

Please order accessories from Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) or our authorized representatives.

CALIBRATION

Traceability: This method has been standardized against the SNIBE internal reference substance.

Test of assay specific calibrators allows the RLU values to adjust the assigned master curve. Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve (10 calibrations) provided via the reagent Radio Frequency Identification (RFID) CHIP.

Recalibration is recommended if any of the following conditions occurs:

- After each change of lots (Reagent or Starter 1+2).
- Every 2 weeks and/or each time a new reagent kit is used (recommended).
- After instrument service is required.

- If control results lie outside the expected range.

QUALITY CONTROL

Follow government regulations or accreditation requirements for quality control frequency.
Internal quality control is only applicable with MAGLUMI and Biolumi systems. For instructions for use and target value refer to ***CA 72-4 (CLIA) Quality Control Information***. User needs to judge results with their own standards and knowledge.
For detailed information about entering quality control values, refer to the corresponding Analyzer Operating Instructions.
To monitor system performance and chart trends, commercially available quality control materials are required. Treat all quality control samples the same as patient samples. A satisfactory level of performance is achieved when analyte values obtained are within the acceptable Control Range for the system or within your range, as determined by an appropriate internal laboratory quality control scheme. If the quality control results do not fall within the Expected Values or within the laboratory's established values, do not report results. Take the following actions:

- Verify that the materials are not expired.
- Verify that required maintenance was performed.
- Verify that the assay was performed according to the instructions for use.
- Rerun the assay with fresh quality control samples.
- If necessary, contact your local technical supporters or distributors for assistance.

SPECIMEN COLLECTION AND PREPARATION

- Use standard sampling tubes or tubes containing separating gel. Collect blood aseptically following the universal precautions for venipuncture.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time.
- If the specimen is centrifuged before a complete clotting, the presence of fibrin may cause erroneous results. Samples must be free of fibrin and other particulate matter.
- Do not use hemolyzed or grossly lipemic specimens as well as specimens containing particulate substance or exhibiting obvious microbial contamination. Inspect all specimens for bubbles, and remove bubbles before analysis for optimal results.
- Avoid repeating freeze-thaw cycles. The serum sample can be only frozen and thawed two times. Specimens must be mixed thoroughly after thawing.
- Centrifuged specimens with a lipid layer on the top must be transferred to a sample cup or a secondary tube. Care should be taken to transfer only the clarified specimen without the lipemic material.
- All samples (patient specimens and controls) should be tested within 3 hours when placed on board the MAGLUMI and Biolumi Systems. Refer to the SNIBE service for more details of onboard sample storage constraints.
- Specimens removed from the separator, cells or clot may be stored up to 30 days at 2-8°C.
- Specimens can be stored up to 3 months frozen at -20°C or colder. Stored samples should be thoroughly mixed prior to use (Vortex mixer).
- Before shipping specimens, it is recommended that specimens be removed from the serum separator, red blood cells or clot. When shipped, specimens should be packaged and labeled in compliance with applicable state, federal and international regulations covering the transport of clinical specimens and infectious substances. Specimens should be shipped frozen.
- The sample volume required for a single determination of CA 72-4 is 40 µL.

WARNING AND PRECAUTIONS FOR USERS

- IVD
- For *In Vitro* Diagnostic Use.
- Follow the package insert carefully. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert.

Safety Precautions

- **CAUTION:** This product requires the handling of human specimens. It is recommended that all human sourced materials be considered potentially infectious and handled in accordance with the 29 CFR 1910.1030 Occupational exposure to bloodborne pathogens. Biosafety Level 2 or other appropriate biosafety practices should be used for materials that contain or are suspected of containing infectious agents.
- All samples, biological reagents and materials used in the assay should be considered potentially able to transmit infectious agents. They should therefore be disposed in accordance with the practices of your institution. Discard all materials in a safe and acceptable manner and in compliance with prevailing regulatory requirements.
- This product contains Sodium Azide. Dispose of contents and containers must be in accordance with all local, regional and national regulations.
- Refer to safety data sheets which are available on request.

Handling Precautions

- Do not use reagent kits beyond the expiration date.
- Do not interchange reagent components from different reagents or lots.
- Prior to loading the reagent kit on the system for the first time, the reagent kit requires mixing to re-suspend magnetic microbeads that have settled during shipment.
- For magnetic microbeads mixing instructions, refer to the Preparation of the Reagent section of this package insert.
- To avoid contamination, wear clean gloves when operating with a reagent kit and samples.
- Over time, residual liquids may dry on the septum surface. These are typically dried salts which have no effect on assay efficacy.
- For detailed discussion of handling precautions during system operation, refer to the SNIBE service information.

STORAGE AND STABILITY

- Sealed: Stored at 2-8°C until the expiration date.
- Opened at 2-8°C: Minimum stability is 4 weeks.
- On-board: Stability is 4 weeks.
- To ensure the best kit performance, it is recommended to place opened kits in the refrigerator after the end of the intraday test work.
- Keep upright for storage to facilitate later proper resuspension of magnetic microbeads.
- Keep away from sunlight.

TEST PROCEDURE

Preparation of the Reagent

- Resuspension of the magnetic microbeads takes place automatically when the kit is loaded successfully, ensuring the magnetic microbeads are

totally resuspended homogenous prior to use.
- To ensure proper test performance, strictly adhere to the corresponding Analyzer Operating Instructions. Each test parameter is identified via a RFID CHIP on the Reagent kit. For further information please refer to the corresponding Analyzer Operating Instructions.

DILUTION

Sample dilution by analyzer is not available in this reagent kit.
Samples with concentrations above the measuring range can be diluted manually. After manual dilution, multiply the result by the dilution factor. Please choose applicable diluents or ask SNIBE for advice before manual dilution.

High-Dose Hook

No high-dose hook effect was seen for CA 72-4 concentrations up to 10,000 U/mL.

LIMITATIONS

- A skillful technique and strict adherence to the instructions are necessary to obtain reliable results.
- Bacterial contamination or heat inactivation of the specimens may affect the test results.
- A result within the expected range does not rule out the presence of disease and should be interpreted together with other diagnostic procedures.
- Test results are reported quantitatively. However, diagnosis of a disease should not be based on the result of a single test, but should be determined in conjunction with clinical findings in association with medical judgement.
- Any therapeutical decision should also be taken on a case-by-case basis.
- Patient samples containing human anti-mouse antibodies (HAMA) may give falsely elevated or decreased values. Although HAMA-neutralizing agents are added, extremely high HAMA serum concentrations may occasionally influence results.

RESULTS

Calculation of Results

The analyzer automatically calculates the Cancer Antigen (CA 72-4) concentration of each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are reported in the unit of U/mL. For further information please refer to the corresponding Analyzer Operating Instructions.

Interpretation of Results

The expected range for the CA 72-4 assay was obtained by testing 314 apparently healthy individuals in China, and gave the following expected value:
<6 U/mL (95^{th} percentile).
Results may differ between laboratories due to variations in population and test method. It is recommended that each laboratory should establish its own expected ranges.

PERFORMANCE CHARACTERISTICS

Precision

Precision for the CA 72-4 assay was determined as described in the CLSI EP5-A2. 2 human serum pools and 3 controls containing different concentration of analyte were assayed in duplicate at two independent runs per day for 20 testing days. The results are summarized in the following table:

Sample	Mean(U/mL) (N=80)	Within-Run		Between-Run		Total	
		SD(U/mL)	%CV	SD(U/mL)	%CV	SD(U/mL)	%CV
Serum Pool 1	61.856	3.627	5.86	1.638	2.65	3.980	6.43
Serum Pool 2	209.075	6.688	3.20	3.046	1.46	7.674	3.67
Control 1	8.863	0.482	5.44	0.550	6.21	0.731	8.25
Control 2	27.532	1.020	3.71	1.470	5.34	1.789	6.50
Control 3	94.372	3.250	3.44	1.971	2.09	3.801	4.03

Limit of Blank (LoB)

The LoB for the CA 72-4 assay is 0.2 U/mL.

Limit of Detection (LoD)

The LoD for the CA 72-4 assay is 0.5 U/mL.

Measuring range

0.2-500 U/mL (defined by the limit of blank and the maximum of the master curve). Values below the limit of blank are reported as <0.2 U/mL. Values above the measuring range are reported as >500 U/mL.

Linearity

The assay is linear between 0.5 U/mL and 500 U/mL based on a study performed with guidance from CLSI EP6-A. Nine equally distributed levels of samples were prepared by blending a serum sample containing CA 72-4 520 U/mL with a serum sample depleted of CA 72-4 (0.0 U/mL).The mean sample recovery ranged between 90% to 110%.

Method Comparison

A total of 115 samples in the range of 0.789 and 438.673 U/mL were tested using the CA 72-4 assay (y) and a commercially available immunoassay (x). The data from the resulting linear regressions are summarized as: $y = 0.945x + 2.1506$, $r^2 = 0.9817$.

Analytical Specificity

The specificity of the assay was obtained by adding CA 125 (800 U/mL), CA 15-3 (800 U/mL) and CA 19-9 (800 U/mL) to two serum samples at the indicated concentrations. No interference was found.

Endogenous Interference

Substances up to the following concentrations did not interfere with the assay:

Interference	Concentration
Bilirubin	65 mg/dL
Hemoglobin	2200 mg/dL
Triglycerides	1500 mg/dL
RF	1500 IU/mL
Cisplatin	165 µg/mL
Bleomycin	30 µg/mL
Carboplatin	500 µg/mL
Fluorouracil	400 µg/mL
Cytarabine	30 µg/mL
Methotrexate	909 µg/mL
mitomycin-C	100 µg/mL
Paclitaxel	67 µg/mL
Vinblastine sulfate	500 µg/mL
Doxorubicin hydrochloride	40 µg/mL
Tamoxifen	0.0228 µg/mL
Cyclophosphamide	1000 µg/mL

REFERENCES

1. Scott, A. M., Wolchok, J. D., & Old, L. J. (2012). Antibody therapy of cancer. *Nature reviews. Cancer*, *12*(4), 278.
2. Ychou, M., Duffour, J., Kramar, A., Gourgou, S., & Grenier, J. (2000). Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. *Disease markers*, *16*(3-4), 105-110.
3. Emoto, S., Ishigami, H., Yamashita, H., Yamaguchi, H., Kaisaki, S., & Kitayama, J. (2012). Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. *Gastric Cancer*, *15*(2), 154-161.
4. Mattar, R., Andrade, C. R. A. D., DiFavero, G. M., Gama-Rodrigues, J. J., & Laudanna, A. A. (2002). Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. *Revista do Hospital das Clínicas*, *57*(3), 89-92.
5. Byrne, D. J., Browning, M. C. K., & Cuschieri, A. (1990). CA72–4: a new tumour marker for gastric cancer. *British Journal of Surgery*, *77*(9), 1010-1013.
6. Tocchi, A., Costa, G., Lepre, L., Liotta, G., Mazzoni, G., Cianetti, A., & Vannini, P. (1998). The role of serum and gastric juice levels of carcinoembryonic antigen, CA19. 9 and CA72. 4 in patients with gastric cancer. *Journal of cancer research and clinical oncology*, *124*(8), 450-455.
7. Li, Y., Yang, Y., Lu, M., & Shen, L. (2010). Predictive value of serum CEA, CA19-9 and CA72. 4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepato-gastroenterology, 58(112), 2166-2170.
8. Holubec Jr, L., Topolcan, O., Pikner, R., Pecen, L., Vaclavickova, J., Wirthova, M., ... & Finek, J. (2000). The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence. Anticancer research, 20(6D), 5237-5244.

Shenzhen New Industries Biomedical Engineering Co., Ltd.
No.23, Jinxiu East Road, Pingshan District, 518122 Shenzhen, P.R. China
Tel: +86-755-21536601 Fax: +86-755-28292740

Shanghai International Holding Corp. GmbH (Europe)
Eiffestrasse 80, 20537 Hamburg, Germany
Tel: +49-40-2513175 Fax: +49-40-255726

SYMBOLS EXPLANATIONS

	Consult instructions for use		Manufacturer
2°C 8°C	Temperature limit (Store at 2-8 °C)		Use-by date
Σ	Contains sufficient for		Keep away from sunlight
	This way up	EC REP	Authorized representative in the European Community
IVD	*In vitro* diagnostic medical device	CONTENTS	Kit components
REF	Catalogue number	LOT	Batch code